ArticleHeart and vessels2026
Prognostic impacts of fibrosis-5 index in patients with chronic heart failure.
Article in Heart and vessels, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fibrosis-5 in patients with chronic heart failure: a participant or a bystander?Heart and vessels · 2026Article
- Response to "Fibrosis-5 in patients with chronic heart failure: a participant or a bystander?"Heart and vessels · 2026Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to evaluate the usefulness of the Fibrosis-5 index (FIB-5) for predicting prognosis in patients with chronic heart failure and examine whether combining the Fibrosis-4 (FIB-4) and FIB-5 indices could enhance risk stratification in heart failure. This single-center retrospective cohort study analyzed data from an inpatient database. A total of 1,100 patients (mean age, 78 years; 58.2% male) were included. The primary endpoint was a composite event (all-cause mortality and rehospitalization for heart failure) within 1 year of hospital discharge, assessed before and after propensity score matching (PSM). Receiver operating characteristic curve analysis identified - 0.85 as the optimal FIB-5 cutoff value for predicting composite events, classifying patients into high- and low-FIB-5 groups. The low-FIB-5 group had significantly higher event rates than the high-FIB-5 group, both before and after PSM. A cubic spline curve analysis showed that lower FIB-5 values were associated with significantly higher composite event rates. In multivariable Cox regression analysis, low FIB-5 (< - 0.85) was significantly associated with the 1-year composite endpoint compared with the high-FIB-5 index. Among patients in the moderate-risk FIB-4 category, those with high FIB-5 values exhibited outcomes comparable to the low-risk FIB-4 group, whereas those with low FIB-5 values showed risks similar to the high-risk FIB-4 group. The FIB-5 index may serve as a useful prognostic marker in patients with chronic heart failure. Combining the FIB-4 and FIB-5 indices enables refined risk stratification by identifying high-risk individuals within the moderate-risk FIB-4 category using only routinely available laboratory parameters.
Indexed as
Identifiers
42321565What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.